



FREQUENTLY ASKED QUESTIONS (FAQs)

# AVEIR™ AR Leadless Pacemaker (LP) System Reimbursement Update

## 1. What changed and when does it take effect?

Effective April 1, 2026, AVEIR AR LP (CPT<sup>®</sup> code 0823T) and AVEIR AR LP Upgrade (CPT<sup>®</sup> code 0796T) moved from APC 5224 to APC 5231. The new national unadjusted Hospital Outpatient Prospective Payment System (OPPS) rate is \$22,725, up from \$19,679—an increase of \$3,046 per case (+15.5%).<sup>1</sup> This payment uplift affects hospital outpatient payment for Medicare beneficiaries. By comparison, ventricular leadless pacemakers continue to be assigned to APC 5224 under OPPS, with a national payment rate of \$19,679.

## 2. Which CPT<sup>®</sup> codes are affected?

- 0823T - Transcatheter insertion of permanent single chamber leadless pacemaker, right atrial (AVEIR AR LP standalone).
- 0796T - Transcatheter insertion of permanent dual chamber leadless pacemaker, right atrial component when an existing right ventricular single leadless pacemaker exists (AVEIR AR LP Upgrade).

## 3. Will this rate change going forward?

Centers for Medicare and Medicaid Services (CMS) reviews APC rates annually through the OPPS rulemaking; the rate may adjust modestly year to year based on cost data, but the APC placement itself is stable.

## 4. Can hospitals retroactively claim the higher rate for procedures before April 1, 2026?

No. The APC 5231 assignment is effective on or after April 1, 2026 only. Procedures performed before April 1, 2026 are correctly paid at APC 5224.

## 5. Why is this important?

The national unadjusted OPPS rate jumped to \$22,725—up \$3,046 (+15.5%) from \$19,679. This increase meaningfully improves outpatient reimbursement for AVEIR AR LP under OPPS and supports payment alignment for the technology in the hospital outpatient setting.

To contact a reimbursement specialist for coverage, coding, or payment questions at [LeadlessReimbursement@Abbott.com](mailto:LeadlessReimbursement@Abbott.com)

<sup>1</sup> Hospital Outpatient Prospective Payment System Transmittal: <https://www.cms.gov/medicare/regulations-guidance/transmittals/2026-transmittals/r13686cp>

**Important Safety Information: AVEIR™ Leadless Pacemaker System**

**Rx Only: Brief Summary:** Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. **Indications for Use:** The AVEIR™ Leadless Pacemaker system is indicated for management of one or more of the following chronic clinical presentations: syncope, pre-syncope, fatigue, disorientation, and one or more of the indications which follow. Rate-modulated pacing is indicated for patients with chronotropic incompetence, and for those who would benefit from increased stimulation rates concurrent with physical activity. Dual-chamber pacing is indicated for patients exhibiting one or more of the following conditions: sick sinus syndrome; chronic, symptomatic second- and third-degree AV block; recurrent Adams-Stokes syndrome; symptomatic bilateral bundle-branch block when tachyarrhythmia and other causes have been ruled out. Atrial pacing is indicated for patients with: sinus node dysfunction and normal AV and intraventricular conduction systems. Ventricular pacing is indicated for patients with significant bradycardia and: normal sinus rhythm with only rare episodes of AV block or sinus arrest, chronic atrial fibrillation. MR Conditional: The AVEIR Leadless Pacemaker is conditionally safe for use in the MRI environment and according to the instructions in the MRI-Ready Leadless System Manual. **Intended Use:** The AVEIR™ Leadless Pacemaker (LP) is designed to provide bradycardia pacing as a pulse generator with built-in battery and electrodes for implantation in the right ventricle and the right atrium. The LP is intended to provide sensing of intrinsic cardiac signals and delivery of cardiac pacing therapy within the implanted chamber for the target treatment group. The LP is also intended to operate optionally with another co-implanted LP to provide dual-chamber pacing therapy. The AVEIR™ Delivery Catheter is intended to be used in the peripheral vasculature and the cardiovascular system to deliver and manipulate an LP. Delivery and manipulation includes implanting an LP within the target chamber of the heart. **Contraindications:** Use of the AVEIR™ Leadless Pacemaker is contraindicated in these cases: • Use of any pacemaker is contraindicated in patients with a co-implanted ICD because high-voltage shocks could damage the pacemaker and the pacemaker could reduce shock effectiveness. • Single-chamber ventricular demand pacing is relatively contraindicated in patients who have demonstrated pacemaker syndrome, have retrograde VA conduction, or suffer a drop in arterial blood pressure with the onset of ventricular pacing. • Programming of rate-responsive pacing is contraindicated in patients with intolerance of high sensor driven rates. • Use is contraindicated in patients with an implanted vena cava filter or mechanical tricuspid valve because of interference between these devices and the delivery system during implantation. • Persons with known history of allergies to any of the components of this device may suffer an allergic reaction to this device. Prior to use on the patient, the patient should be counseled on the materials (listed in the Product Materials section of the IFU) contained in the device and a thorough history of allergies must be discussed. **Adverse Events:** Potential complications associated with the use of the AVEIR™ Leadless Pacemaker system are the same as with the use of single or dual chamber pacemakers with active fixation pacing leads including, but not limited to: cardiac perforation; cardiac tamponade; pericardial effusion; pericarditis; endocarditis; thrombus formation; thromboembolism; valve damage or regurgitation; heart failure; pneumothorax/hemothorax; cardiac arrhythmias; diaphragmatic/phrenic nerve stimulation / extra-cardiac stimulation; palpitations; hypotension; syncope; cerebrovascular accident; infection; hypersensitivity reaction to device materials, medications, contrast media, or direct toxic effect of contrast media on kidney function; pacemaker syndrome; inability to interrogate or program the LP due to programmer or LP malfunction; intermittent or complete loss of capture, pacing or sensing (non-battery related); oversensing; increased capture threshold; inappropriate sensor response; corrupted, intermittent, or loss of i2i communications; interruption of desired LP function due to electrical interference, either electromyogenic or electromagnetic; battery malfunction/ premature battery depletion; device-related complications (premature deployment, device dislodgement/embolization of foreign material, inability to release/re-dock of the LP from catheter, helix distortion); additional surgery or intervention; death. As with any percutaneous catheterization procedure, potential complications include, but are not limited to: vascular access complications, such as perforation, dissection, puncture, groin pain; bleeding or hematoma; thrombus formation; thromboembolism; air embolism; local and systemic infection; peripheral nerve damage; general surgery risks and complications from comorbidities; such as dyspnea, respiratory failure, pneumonia, hypertension, cardiac failure, reaction to sedation, renal failure, anemia, and death. Refer to the User's Manual for detailed indications, contraindications, warnings, precautions, and adverse events.

**Disclaimer:** This material and the information contained herein is for general information purposes only and is not intended, and does not constitute, legal, reimbursement, business, clinical, or other advice. Furthermore, it is not intended to and does not constitute a representation or guarantee of reimbursement, payment, or charge, or that reimbursement or other payment will be received. It is not intended to increase or maximize payment by any payer. Abbott makes no express or implied warranty or guarantee that the list of codes and narratives in this document is complete or error-free. Similarly, nothing in this document should be viewed as instructions for selecting any particular code, and Abbott does not advocate or warrant the appropriateness of the use of any particular code. The ultimate responsibility for coding and obtaining payment/reimbursement remains with the customer. This includes the responsibility for accuracy and veracity of all coding and claims submitted to third-party payers. In addition, the customer should note that laws, regulations, and coverage policies are complex and are updated frequently, and, therefore, the customer should check with its local carriers or intermediaries often and should consult with legal counsel or a financial, coding, or reimbursement specialist for any questions related to coding, billing, reimbursement, or any related issues. This material reproduces information for reference purposes only. It is not provided or authorized for marketing use.

**CAUTION:** Product(s) intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at [www.eifu.abbott](http://www.eifu.abbott) for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

**Abbott**

3200 Lakeside Dr., Santa Clara, CA 95054 USA Tel: 1.800.227.9902

[www.cardiovascular.abbott](http://www.cardiovascular.abbott)

™ Indicates a trademark of the Abbott group of companies.

‡ Indicates third party trademark, which is the property of its respective owner.

©2026 Abbott. All rights reserved.



See Important Safety Information referenced within.

Information contained herein for DISTRIBUTION in the U.S. ONLY. MAT-2603041 v1.0